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Background: Patients with no history of stroke but with stenosis of the carotid arteries can reduce the risk of
future stroke with surgery or stenting. At present, a physicians’ ability to recommend optimal treatments based on
an individual’s risk profile requires estimating the likelihood that a patient will have a poor peri-operative outcomes
and the likelihood that the patient will survive long enough to gain benefit from the procedure. We describe the
development of the CArotid Risk Assessment Tool (CARAT) into a 2-year mortality risk calculator within the electronic
medical record, integrating the tool into the clinical workflow, training the clinical team to use the tool, and assessing
the feasibility and acceptability of the tool in one clinic setting.
Methods: We modified an existing clinical flowsheet with the local electronic medical record for the CARAT risk model.
To understand how CARAT would fit into the existing clinical workflow, we observed the clinic and talked with the
clinical staff to develop a process map for the existing clinical workflow. CARAT was completed by the clinic nurse for
patients identified on the clinic schedule as having carotid narrowing. We analyzed post-implementation assessment in
two ways: quantifying the proportion of eligible patients with whom CARAT was utilized, and surveying surgeons to
understand the impact of CARAT on decision-making and clinical workflow.
Results: With minimum investment of institutional resources, we were able to produce a workable tool and pilot the
tool in our clinic within a 6 month time period. Over 4 months, 287 patients were seen in the clinic with carotid
narrowing, and clinic staff completed CARAT for 195 (68%). Per-surgeon completion rates ranged from 29 to 81%.
Most patients (191 of 195, 98%) patients had a low 2-year calculated mortality risk. Most surgeons believed the risk
assessment aligned with their expectations of patient predicted risk.
Conclusions: We successfully integrated CARAT into the existing electronic medical record and have preliminary
evidence that CARAT can be a valuable tool for evaluating mortality risk for patients with diseased carotid arteries.
Accuracy of the risk calculations must be evaluated in larger, multi-center studies.
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Table 1 Factors associated with increased 2-year mortality
following carotid revascularization and the points each
factor is given in calculating the CARAT risk score
Patient characteristic Points




2. Insulin-requiring diabetes 2
3. CHF; Asymptomatic 2
CHF; Symptomatic 4
4. COPD; Mild/moderate 2
COPD; Oxygen dependent 4
5. Smoker; Past history or current 1
6. Renal function; eGFR < 60 3
Dialysis dependent 4





8. Not on statin 1
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For patients with stenosis (i.e. narrowing) of the carotid
arteries, revascularization with surgery or stenting to re-
lieve the blockage has an important benefit - reducing
the risk of future stroke [1-4]. Evidence from random-
ized trials is clear for “symptomatic” patients who have
already suffered a minor stroke due to these blockages.
These patients have a greater than 20% annual risk of
subsequent stroke without carotid revascularization, so
nearly all patients choose revascularization to help limit
their chances of suffering another, potentially more
debilitating stroke [5-8].
However, revascularization is also recommended for
patients with “asymptomatic” carotid stenosis – where
patients have narrowed carotid arteries but have not had
any symptoms such as a preceding stroke [6,8]. Patients
with asymptomatic carotid stenosis have a much lower
annual risk of stroke than those who have already had
an event – approximately 3% per year in each year of
the patient’s remaining life expectancy. The absolute
benefit of revascularization is uncertain for many pa-
tients with asymptomatic carotid stenosis [6]. Determin-
ing the optimal treatment choice for a patient with
asymptomatic carotid stenosis must carefully weigh sev-
eral competing risks: the up-front risks of revasculariza-
tion, the long-term risk of stroke, and the patient’s life
expectancy [9-11]. While the short-term risks have been
described, the long term risks are less well known. At
present, a physicians’ ability to recommend optimal
treatments based on an individual’s risk profile can be
difficult, because they must quickly integrate two com-
plex risks: the likelihood that a patient will have a poor
peri-operative outcome, and the likelihood that the pa-
tient will survive long enough to garner benefit from the
procedure [6-8].
Therefore, we developed and pilot-tested a health in-
formation technology tool to help physicians and pa-
tients better understand these two risks [12]. First, we
used short-term surgical risk stratification, from the
detailed patient and procedural variables present in our
national vascular registry, the Vascular Quality Initiative
(VQI) to help clinicians identify those patients who are
likely to fare poorly with carotid revascularization. Sec-
ond, we used five-year longitudinal follow-up from a
linked carotid-Medicare claims VQI dataset to assess the
effectiveness of carotid revascularization in preventing
stroke during the patient’s remaining life expectancy. In
a previous publication, we described the variable construc-
tion and preliminary validation of the carotid risk assess-
ment tool (CARAT) [Jessica B. Wallaert, Karina A. Newhall,
Bjoern D. Suckow, Benjamin S. Brooke, Min Zhang, Adrienne
E Faerber, Donald Likosky, Phillip P Goodney: Development
of a model to predict long-term survival and stroke-related
costs following asymptomatic carotid revascularization,under review]. In this manuscript, we describe the de-
velopment of CARAT into a clinician decision support
tool within the electronic medical record (EMR), integrat-
ing the tool into the clinical workflow, training the clinic
staff to use the tool, and assessing the feasibility and
acceptability of the tool in one clinic setting. We hypothe-
sized that it would be feasible to implement CARAT
within the EMR and clinical workflow, that the clinic staff
would use the tool, and that the tool would be acceptable
to surgeons.
Methods
The CARAT risk model
In previous work, we describe the generation and valid-
ation of the risk model upon which CARAT is based
[Jessica B. Wallaert, Karina A. Newhall, Bjoern D. Suckow,
Benjamin S. Brooke, Min Zhang, Adrienne E Faerber,
Donald Likosky, Phillip P Goodney: Development of a
model to predict long-term survival and stroke-related costs
following asymptomatic carotid revascularization, under
review]. CARAT uses individual characteristics of the pa-
tient with a carotid artery condition (age, smoking status),
comorbidities (diabetes, CHF, COPD, renal function),
statin use, and extent of carotid narrowing to calculate a
risk score that predicts 2-year mortality (Table 1). The risk
score ranges from 0 to 20, where lower scores indicate
lower 2-year mortality. Scores are stratified into three
validated risk tiers: 0–10 is “safe for surgery”, 11–14
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be indicated based on limited life expectancy,” (Table 2).
Developing CARAT in an electronic medical record
Our previous experience with designing risk assessment
tools showed us that direct EMR integration (versus a pen-
and-paper form) would offer better usability and utility for
CARAT, hence focused on developing CARAT for an exist-
ing EMR. We chose the EMR currently used in our clinical
setting, which is Epic. We worked in collaboration with
Epic designers to modify an existing clinical flowsheet for
the CARAT risk model, which provided a simpler and
quicker process for implementing the tool in the EMR.
Engaging key stakeholders
Several key stakeholders were engaged in developing
CARAT within our EMR. These stakeholders varied from
EMR designers and analysts who modified the existing
flowsheet for our risk tool, clinic nurses who collected and
entered the necessary data elements, and surgeons who
interpreted the output from CARAT. Each stakeholder
was offered key opportunities to participate in the process
development and provide feedback and input. This
process occurred over four months via group meetings,
surveys, and individual consults. Meetings with EMR
developers allowed us to integrate our findings into the
electronic record in a user-friendly fashion. Discussions
with clinic staff (surgeons, nurse practitioners, nurses, and
medical assistants) reviewed the steps necessary to use the
tool. Finally, discussions with patient development part-
ners reviewed the steps necessary to use the tool during a
clinical encounter.
Workflow integration & clinic staff training
The pilot feasibility study of CARAT as a medical calcu-
lator took place in a tertiary vascular surgical clinic at anTable 2 Risk scores, mortality prediction and decision
support messages for CARAT
Risk score Predicted 2-year mortality Decision support message





11-12 21% Consider Surgery
Carefully
13-14 34%
15-16 51% Surgery May Not Be
Indicated, Based on
Limited Life Expectancy17-18 70%
19-20 88%
>20 99%
Risk scores are calculated from the factors in Table 1.academic medical center in New Hampshire, United
States. To understand how CARAT would fit into the
existing clinical workflow, we observed the clinic and
talked with the clinic staff to develop a process map for
the existing clinical workflow (Table 3). From the process
maps, we discussed possible ways to integrate CARAT
into the clinical workflow. In the workflow (Figure 1),
CARAT was completed by the clinic nurse for patients
identified on the clinic schedule as having a carotid condi-
tion (indicated by a completed carotid ultrasound). The
resulting risk score was then available as part of the med-
ical record (along with the ultrasound, medical history,
and other relevant laboratory tests) for the surgeon to re-
view before discussing treatment options with the patient.
A surgeon or nurse practitioner provided the risk estimate
to the patient. Discussions regarding the language used to
communicate risks to the patients were particularly
challenging to develop, as surgeons expressed concerns
regarding liability and decision-making. For example, sur-
geons did not want the language to limit their ability to
offer surgery to patients who were potentially high-risk,
but had clinical indications that pre-empted the advice of-
fered by our risk prediction tool.
The clinical staff was trained to use CARAT in a group
training session followed by individual consults with the
project team as implementation rolled out. Training ses-
sions included clinic nurses, medical assistants, and recep-
tionists. Training session objectives were to illustrate how
to complete CARAT in the EMR, provide opportunities
for the clinical team to complete CARAT in a “sandbox”
environment, and solicit feedback from the clinical team
on integrating CARAT into the workflow.
Feasibility and acceptability of CARAT
Once CARAT had been created and integrated into
the EMR within our vascular surgery clinic, we evalu-
ated the feasibility and acceptability of the tool. We
analyzed post-implementation assessment in two ways:
quantifying the proportion of eligible patients with
whom CARAT was utilized, and surveying surgeons to
understand the impact of CARAT on decision-making
and clinical workflow. This survey asked surgeons about
using CARAT, whether CARAT results were in con-
cordance with their expectations, when CARAT wouldTable 3 Clinic staff










































































Figure 1 Proposed and actual use of CARAT in clinic workflow. As proposed, CARAT would be used early in the workflow and completed by
an intake nurse and reviewed by the surgeon before the clinical encounter. In practice, CARAT was completed by the clinic nurse and reviewed
by the surgeon before or after the consultation.
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clinical encounters. These data were evaluated using exist-
ing clinical information systems within our EMR, as well
as surveys distributed to the surgeons who saw patients
within our clinic (n = 10). All analyses were performed
using SAS (Cary, NC) and STATA 12 MP (College Station,
TX). Dartmouth’s Committee for the Protection of
Human Subjects approved our research protocol and
approved the waiver of need for informed consent.
Results
Developing CARAT in an electronic medical record
At our institution, the development process for most
new tools in the EMR involves a lengthy process of spe-
cifying inputs, designing and testing the user interface,
integrating existing EMR data with the new tool and de-
signing outputs like reports or analysis datasets. Though
this process would produce a tool with good usability
and integration, we opted instead to take a faster ap-
proach to development by modifying an existing func-
tion within the EMR that would suit our needs. This
meant that we did not have an ideal interface, nor did
we have customized reports on the use of the tool. But,
with minimum investment of institutional resources, we
were able to produce a workable tool and pilot the tool
in our clinic within a 6 month time period.
Workflow integration & clinical team training
It was anticipated that the CARAT score would be cal-
culated during the referral and intake process, before theclinic visit to discuss treatment options for carotid sten-
osis. This approach would potentially allow surgeons to
know the patient’s 2-year estimated post-surgical mortal-
ity before scheduling the patient for an appointment.
However, after reviewing existing clinic workflow, the
clinic staff chose to integrate CARAT within the nursing
intake of the patient on the day of the clinic visit. In-
stead of being completed by a nurse at the time of refer-
ral, CARAT was completed by a nurse on the day of the
visit as part of the standard nursing assessment and col-
lection of data prior to patient being seen by the surgeon.
Additionally, we had intended CARAT to be included in
the medical record before the day of the visit to allow sur-
geons time to review CARAT before the clinical encoun-
ter and to tailor their discussion of treatment options
based on the results of CARAT. With CARAT integrated
as a component of usual vitals of the carotid patient upon
entry to clinic, the data was available to the surgeon
if s/he chose to view prior to or during time with the
patient in the exam room. There was not observed
consistency in patterns of behavior amongst surgeons and
nurse practitioners in viewing the results of CARAT: some
surgeons and nurse practitioner viewed the results before
consultation, allowing them to tailor their discussion of
treatment options, while others used the consultation as
an opportunity to gather more information and consulted
with the completed CARAT after the consultation. A few
surgeons were able to tailor their discussion of treatment
options, although few described this as a discrete disad-
vantage during our post-implementation survey.
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We pilot tested the CARAT tool by examining how
commonly it was used by providers, and surveying pro-
viders regarding the utility of the tool. For four months
after the clinic began using the tool, we assessed the
feasibility of our CARAT tool by quantifying how often
the tool was used. We performed a clinical audit to cap-
ture the number of patients eligible for CARAT assess-
ment as well as the number of patients in whom CARAT
was actually performed and viewed by the physician.
Over the four month assessment period, 287 patients
were seen in the clinic who had a preliminary diagnosis
of carotid stenosis which met the threshold for surgery
(greater than 70% blockage), and had a recent ultrasound
confirming the degree of stenosis, so were potentially eli-
gible for CARAT. Clinic staff completed the CARAT for
195 (68%). All of the surgeons and nurse practitioners in
the clinic (n = 10) used CARAT for their patients, and
completion rates ranged from 29 to 81%. Completion
rates were most variable for surgeons that saw fewer than
10 patients during the study period (range 29% to 80%).
For surgeons and nurse practitioners that saw more than
10 patients, completion rates were between 42 to 81%.
Almost all patients were assessed as having low risk
(scores from 1–10 points) on CARAT. In our population
of elective patients referred for carotid artery stenosis,
only 4 had medium risk (11–14), and none had high
risk characteristics during our study period. The dis-
tribution of patients among the three risk groups was
similar to the distribution of scores in model develop-
ment [Jessica B Wallaert KAN, Bjoern D. Suckow,
Benjamin S. Brooke, Min Zhang, Adrienne E Faerber,
Donald Likosky, Phillip P Goodney: Development of a
model to predict long-term survival and stroke-related
costs following asymptomatic carotid revascularization,
under review].
Finally, we sought to assess the acceptability of CARAT
by surveying the surgeons and nurse practitioners who
saw patients in the clinic where CARAT was implemen-
ted. Eight of the 10 surgeons and nurse practitioners who
used the CARAT tool completed a survey. Three surgeons
or nurse practitioners did not recall entering data into the
CARAT tool itself, because other members of the clinic
staff (nurses, medical assistants) completed the tool for
them. Of the remaining 5 surgeons or nurse practitioners
who recall using CARAT, 4 of 5 believed that CARAT
results aligned with their expectations, while one was un-
sure if the risk prediction generated by CARAT aligned
with their expectations.
We asked surgeons and nurse practitioners questions
to determine their views about the optimal time during
the episode of care for carotid artery stenosis to use
CARAT. Options for use of the tool varied from the
time of primary care provider visit through the occurrenceof specialty services such as consultation, imaging, or even
just before surgery. Nearly all surgeons or nurse prac-
titioners agreed that primary care was not the ap-
propriate place (7 of 8) because questions regarding the
appropriateness of surgery could not be reliably an-
swered in that setting. However, surgeons and nurse
practitionersdisagreed as to the optimal time period to
use the CARAT tool: upon referral to vascular services
(3 of 8 supporting), at time of testing (3 of 8), during the
pre-visit chart review (2 of 8), or when discussing treat-
ment options (2 of 8).
Lastly, we asked about the value that CARAT can add
to assessing risk of the patient with asymptomatic carotid
stenosis. All surgeons and nurse practitioners (8 of 8)
agreed that CARAT provides value in adding objective
evidence to clinician recommendations. Further, 7 of 8
stated that CARAT supports informed decision-making by
the patient, 4 of 8 stated that CARAT increased their con-
fidence in making a recommendation in favor of - or
against - surgery. Half of surgeons and nurse practitioners
(4 of 8) felt that CARAT provided value in building regis-
try data for advancing outcomes-based research. And
finally, when we asked surgeons and nurse practitioners to
describe positive attributes of CARAT being embedded in
the patient record, 6 of 8 reported the ability to document
of the values generated by CARAT, 5 of 8 reported the
ability to share these data among medical providers, and 4
of 8 said ease of access. No negative comments about
EMR integration were offered by the surgeons and nurse
practitioners.
Discussion
In this project, we developed the Carotid Risk Assess-
ment Tool (CARAT), a risk calculator, into our elec-
tronic medical record (EMR), integrated the tool into
clinical workflow, trained staff to use the tool and evalu-
ated feasibility and acceptability of CARAT. CARAT is
designed to help physicians make better choices when
faced with decisions surrounding revascularization for
asymptomatic carotid artery stenosis.
The first two steps -development and EMR integration
necessitated a multidisciplinary approach, including
statistical consultants, EMR technology development
experts, implementation scientists, clinical faculty, and
patients. While our third step – implementation of
the tool in a clinical setting – was also multidisciplin-
ary, these team members were the more common
members involved in healthcare related interactions,
such as surgeons, nurses, and clinic staff. We found
that this team - which incorporated team members
from heterogeneous backgrounds working together in
a multi-faceted approach – was able to effectively and effi-
ciently design and implement our Health IT tool aimed at
limiting unnecessary carotid revascularization.
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bers led us to agree that our efforts to design and imple-
ment CARAT were successful because we used two key
approaches: team-based interactions and workflow inte-
gration. First, our team-based interaction meant that we
worked directly with our Health IT implementation team
to generate an interface where the CARAT data could be
easily and efficiently entered in a manner that did not
interfere with clinic flow. Second, in terms of workflow in-
tegration, we allocated time and dedicated effort within
the CARAT implementation process for nursing flow and
education in garnering the necessary information to gen-
erate the risk score in CARAT (Figure 1). This allowed the
“work” of CARAT data collection to be incorporated into
clinic workflow as a distinct, new element, with a specific
team member assigned to this task, yet simply assimilated
into existing activities. This helped us have accountability
in this effort across a multidisciplinary team [13]. Further,
we designed the CARAT EMR interface in Epic to allow
the physicians and other health care providers to quickly
and promptly gain access to the necessary information
contained in CARAT. This allowed all team members –
not just the surgeons using the tool – to know which
elements were necessary to collect, and how they were
integrated into the tool. The combination of these three
approaches allowed us to develop and implement CARAT
in a fashion that quickly and conveniently conveyed the
necessary information to providers.
Next steps: examining the effect of EMR-based decision
tools on patient decisions
While it is challenging to design EMR-based decision-
tools in a way so that providers actually use the tools, it
is equally important to design the tools so that key
stakeholders – project leaders, collaborators, and project
supporters – can determine if the tools are being used,
and used successfully. Our work was able to easily ac-
complish the former, as it was clear which patients had a
clinical encounter involving carotid stenosis, and we
could easily audit Epic for CARAT scores. The latter –
determine if the tool was used successfully, and actually
affected clinical decisions – remains undescribed at
present. Additionally, this pilot study did not evaluate
the extra time or cost needed to use CARAT, leaving
unanswered whether or not this intervention is cost-
effective. In other words – did the use of CARAT result
in fewer unnecessary carotid interventions? Did patients
and providers feel that they had better quality of shared
decision making? Was decisional regret less common in
patients who used the decision tool? How much extra
cost was incurred using CARAT? Our current study did
not answer these questions. However, we have taken the
initial steps in building the foundation necessary for
these experimental approaches.Our future work aims to explore these questions using
validated instruments and approaches, as well as tools
that will educate not only providers, but integrate with
patients directly (optiongrids.org). We will translate the
lessons learned in building the initial CARAT tool – in
terms of the tool itself, how it was implemented, and
how it was studied – in our next patient-centered version
of CARAT.
Limitations
Our study has several limitations. First, we implemented
CARAT in a single center, which used a single EMR
(Epic). While this implementation was successful in
allowing providers to use CARAT, broader implementa-
tion in multiple centers will be necessary to ensure our
approach is generalizable. Second, in implementing
CARAT in this clinic, we needed to be prescriptive as to
where the tool would fit into the clinic workflow, and
this may limit the ability of the clinic staff to use the tool
in the way they find most useful. Future studies will
allow more flexibility in use of the tool to fit into exist-
ing workflows and to be used when perceived as useful.
Third, we only have information about patients for
whom CARAT was completed, and no information
about the patients for whom CARAT was not com-
pleted, thus affecting the generalizability of the patient-
level findings. Future studies incorporating a control
arm will address this limitation. Fourth, the survey was
fielded to a small number of providers and the results
were heterogeneous. Because of the small size of the
clinic staff, we will need to repeat the survey in a larger
multicenter trial to obtain generalizable results about
different members of the clinic staff. Fourth, as we out-
lined above, the effect of the CARAT tool on utilization
and decision quality remains to be performed, and will
benefit from the multisite settings we will develop in our
future work. We will focus these questions not only on
the provider’s perception of utility, but also incorporate
patient perceptions of the utility of the tool as well. And
finally, while our preliminary analyses suggested that
providers understood the language and presentation in
the risk tool, we will need definitive examination of how
patients and their providers understand and interpret
the information the CARAT tool provided during the
clinical interaction.
Conclusions
In this project, we developed the Carotid Risk Assessment
Tool (CARAT), a risk calculator, into our electronic med-
ical record (EMR), integrated the tool into clinical work-
flow, trained staff to use the tool and evaluated feasibility
and acceptability of CARAT. A multidisciplinary approach
was an important aspect of implementing CARAT within
our center, and helped facilitate effective adoption of the
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asymptomatic carotid artery stenosis. Our future work
will expand the scope and the depth of evaluation of our
tool, as we strive towards our goal of improving decision
quality for patients faced with difficult surgical challenges.
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